Home
Submit New Manuscript
Manuscripts in Draft (
0
)
Pending Revisions (
0
)
Manuscripts in Review (
0
)
Accepted Manuscripts (
0
)
Rejected Manuscripts (
0
)
Manuscripts in Review (
0
)
Co-Author History (
0
)
Home
Pending Review (
0
)
Expired/Declined (
0
)
Accepted Manuscripts (
0
)
Rejected Manuscripts (
0
)
Menu
Disease
A-Z
Health Topics
Alternative Medicine
Developmental Pediatrics
General Pediatrics
Genetics
Immunodeficiencies
Infectious Diseases
Laboratory Medicine
Neonatology
Nutrition
Pediatric Cardiology
View all Topics
Featured Articles
Hypospadias
Skin allergies
Cushing's syndrome
Urticaria (hives) and angioedema
Anal itching
Anaphylaxis
Kids Corner
Health and Knowledge with fun.
Drugs &
Calculators
Medical Calculators
Drug Calculators
Genetic Calculators
Growth Calculators
View all Calcualtors
Drug Index
ACE inhibitor
Alkylating agents
Allergies
View all Drugs
Poisoning Center
Aluminum phosphide
Anti-histaminics
Antidepressants
View all Drugs
Medical Eqipments
Monitors
Pumps
Incubators
View all Equipments
Diagnostic Aid
Get your diffrential
diagnosis.
Consult
& Posts
Ask a Doctor
Diagnostic Dilemma
Question of the Week
Pediatric Blogs
Spot Diagnosis
Grand Rounds
Pedi Poll
Pediatric
Journal
Current Issue
All Issues
Advance Access
About the Journal
Submit Article
Books
& Apps
Book Store
Pediatric Oncall
Medical Calculators
Vaccine Reminder
Pediatric Oncall Journal
Drug Center
Parenting
CME &
Videos
Upcoming Conferences
Conference Abstracts
MCQs
Videos
Vaccine
Reminder
Sign In
Pediatric News
Recent Advancements in the Development of Tuberculosis Vaccine
Apurva Shrigiriwar
More..
01 Jun, 2019
Tuberculosis (TB) is the most common infectious cause of death in the world. About a third of the world’s population is affected by TB. According to the world health organization (WHO), an estimated 10 million new cases of TB were detected in 2017 amongst which 27% cases were in India. The goal of WHO’s End TB Strategy is to bring about a 95% reduction in TB mortality and a 90% reduction in TB incidence by 2035. With the increasing emergence of multidrug-resistant TB and extensively-drug resistant TB, the development of new TB vaccines has become pivotal to achieve these goals.
Currently, Bacille Calmette Guerin (BCG) is the only Food and Drug Administration (FDA) approved vaccine against TB. However, major drawbacks such as inconsistent efficacy against pulmonary TB, especially in adults and adolescents and contraindication in HIV exposed infants have increased the need to develop new vaccines. A number of hurdles have to be overcome to pave the way for developing TB vaccines. As of 2018, about 22 vaccine candidates are included in the Clinical and preclinical TB vaccine pipeline in varying stages of development. Out of these 22 vaccine candidates, about 14 vaccine candidates are currently in clinical trials. A Chinese candidate Vaccae is the only vaccine candidate that has entered phase 3 of clinical testing. A phase 2b clinical trial involving M72/AS01E vaccine candidate showed a 54 % protection against pulmonary tuberculosis over a period of 2 years. Phase 2 trials on the safety and immunogenicity of this vaccine candidate are ongoing. This clinical trial demonstrates that there is tremendous scope for curbing TB with the development of new TB vaccines as there is a potential to overcome the limitation of the BCG vaccine.
A major downside of many vaccines is that a temperature controlled system is required during transport to maintain the efficacy of the vaccine, which can be costly. A thermostable vaccine candidate is being developed by scientists at the Infectious Disease Research Institute (IDRI) in Seattle to overcome this drawback. These scientists are developing a freeze-dried powder formulation of ID93 recombinant vaccine candidate which has been shown to be safe and immunogenic in a Phase 2a clinical trial. Investigations are being carried out to determine the efficacy of the product made by combining sterile water with a single vial containing freeze-dried ID93 and an adjuvant GLA-SE (an immune response-stimulating protein).
A collaborative approach between researchers and the government is the need of the hour as adequate funding is required to carry out these researches. Hopefully, a new vaccine becomes available in the near future to curb the menace called TB.
References:
1. https://www.who.int/immunization/research/development/tuberculosis/en/
2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4530405/
3. https://www.nih.gov/news-events/news-releases/temperature-stable-experimental-tuberculosis-vaccine-enters-clinical-testing
×
Author Information
Apurva Shrigiriwar
News Date :
06/01/2019
Recent Advancements in the Development of Tuberculosis Vaccine
/pediatric-news/recent-advancements-in-the-development-of-tuberculosis-vaccine/22
06/01/2019
Ask a Doctor
Book Store
Dengue, Malaria, Leptospirosis & Typhoid
Order Now
Recommended for you
Inflammatory Bowel Disease (IBD)
Sitz Bath
Torticollis
Videos
Skin Hemangiomas with Limb Hypertrophy
Massive abdominal distention in a 4 year old! Can you guess why?
Uncovering the Cause of a Child's Recurring Bleeding Episodes
View All
Spot Diagnosis
Axillary swelling after vaccine
Unusual case of cervical swelling
Neonatal lupus erythematosus - a cause to remember in newborn dermatosis
View All
Pediatric Oncall Journal
Original Article
Fever without a source under 3 months of age: any predictive factors of Serious Bacterial Infection?
Images In Clinical Practice
A neonate with Erythematous rash over face
Grand Rounds
Asymptomatic Congenital Parvovirus infection in a neonate born to an asymptomatic mother with Parvovirus infection in the third trimester - Management issues
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
X
Sign In
Disease A-Z
Health Topics
Alternative Medicine
Developmental Pediatrics
General Pediatrics
Genetics
Immunodeficiencies
Infectious Diseases
Laboratory Medicine
Neonatology
Nutrition
Pediatric Cardiology
View all topics
Featured Articles
Hypospadias
Skin allergies
Cushing's syndrome
Urticaria (hives) and angioedema
Anal itching
Anaphylaxis
Kids Corner
Drugs & Calculators
Medical Calculators
Drug Calculators
Genetic Calculators
Growth Calculators
View all Calculators
Drug Index
ACE inhibitor
Alkylating agents
Allergies
View all Drugs
Poisoning Center
Aluminum phosphide
Anti-histaminics
Antidepressants
View all Drugs
Medical Eqipments
Monitors
Pumps
Incubators
View all Eqipments
Diagnostic Aid
Consult & Posts
Ask a Doctor
Diagnostic Dilemma
Question of the Week
Pediatric Blogs
Spot Diagnosis
Grand Rounds
Pedi Poll
Pediatric Oncall Journal
Current Issue
All Issues
Advance Access
About the Journal
Submit Article
Books & Apps
Book Store
Pediatric Oncall
Medical Calculators
Vaccine Reminder
Pediatric Oncall Journal
Drug Center
Parenting
CME & Videos
Upcoming Conferences
Conference Abstracts
MCQs
Videos
Vaccine Reminder
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0